S3-Guideline on diagnostics, therapy and follow-up of malignant ovarian tumours;S3-Leitlinie Diagnostik, Therapie und Nachsorge maligner Ovarialtumoren

Geburtshilfe und Frauenheilkunde

Volumn 73, Issue 9, 2013, Pages 874-889

  Wagner, U ^a   Harter, P ^b   Hilpert, F ^b   Mahner, S ^b   Reuss A ^b   Du Bois, A ^b   Petru, E ^b   Meier, W ^b   Ortner, P ^b   Konig K ^b   Lindel, K ^b   Grab, D ^b   Piso, P ^b   Ortmann, O ^b   Runnebaum, I ^b   Pfisterer, J ^b   Luftner D ^b   Frickhofen, N ^b   Grunwald F ^b   Maier, B O ^b   Diebold, J ^b   Hauptmann, S ^b   Kommoss, F ^b   Emons, G ^b   Radeleff, B ^b   Gebhardt, M ^b   Arnold, N ^b   Calaminus, G ^b   Weisse, I ^b   Weis, J ^b   Sehouli, J ^b   Fink, D ^b   Burges, A ^b   Hasenburg, A ^b   Eggert, C ^b   more..

^a Uni Frauenklinik   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; BLEOMYCIN; CA 125 ANTIGEN; CARBOPLATIN; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; IFOSFAMIDE; PACLITAXEL; TOPOTECAN;

ADD ON THERAPY; ADJUVANT CHEMOTHERAPY; ADVANCED CANCER; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER GRADING; CANCER GROWTH; CANCER PALLIATIVE THERAPY; CANCER PREVENTION; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER REHABILITATION; CANCER RESISTANCE; CANCER SCREENING; CANCER STAGING; CANCER SURGERY; EVIDENCE BASED PRACTICE; FOLLOW UP; G2 PHASE CELL CYCLE CHECKPOINT; GENETICS; HEALTH CARE QUALITY; HUMAN; INFORMED CONSENT; MULTIPLE CYCLE TREATMENT; OVARIAN GERM CELL TUMOR; OVARY CANCER; OVARY TUMOR; PATIENT CARE; PATIENT COUNSELING; PRACTICE GUIDELINE; PSYCHOSOCIAL CARE; RISK FACTOR; TREATMENT DURATION;

EID: 84886874560     PISSN: 00165751     EISSN: 14388804     Source Type: Journal    
DOI: 10.1055/s-0033-1350713     Document Type: Article

References (238)

1. Scottish Intercollegiate Guidelines Network SIGN #75: Epithelial ovarian cancer. A national clinical guideline. Scottish Intercollegiate Guidelines Network: 2003
2. The Australian Cancer Network and National Breast Cancer Centre Clinical practice guidelines for the management of women with epithelial ovarian cancer. Camperdown, NSW National Breast Cancer Centre: 2004
3. Menon U. et al. Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Lancet Oncol: 2009; 10 327 340
4. Kobayashi H. et al. A randomized study of screening for ovarian cancer: a multicenter study in Japan. Int J Gynecol Cancer: 2008; 18 414 420 (Pubitemid 351668303)
5. Buys S. S. et al. Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. JAMA: 2011; 305 2295 2303
6. Fung M. F. et al. Screening postmenopausal women for ovarian cancer: a systematic review. J Obstet Gynaecol Can: 2004; 26 717 728
7. van Nagell J. R. Jr. et al. Long-term survival of women with epithelial ovarian cancer detected by ultrasonographic screening. Obstet Gynecol: 2011; 118 1212 1221
8. Timmerman D. et al. Simple ultrasound-based rules for the diagnosis of ovarian cancer. Ultrasound Obstet Gynecol: 2008; 31 681 690
9. Timmerman D. et al. Terms, definitions and measurements to describe the sonographic features of adnexal tumors: a consensus opinion from the International Ovarian Tumor Analysis (IOTA) Group. Ultrasound Obstet Gynecol: 2000; 16 500 505 (Pubitemid 32158133)
10. Karlan B. Y. et al. Peritoneal serous papillary carcinoma, a phenotypic variant of familial ovarian cancer: implications for ovarian cancer screening. Am J Obstet Gynecol: 1999; 180 917 928 (Pubitemid 29200558)
11. Moller P. et al. The BRCA1 syndrome and other inherited breast or breast-ovarian cancers in a Norwegian prospective series. Eur J Cancer: 2001; 37 1027 1032 (Pubitemid 32397689)
12. Taylor L., Schwarz H. Identification of a soluble OX40 isoform: development of a specific and quantitative immunoassay. J Immunol Methods: 2001; 255 67 72 (Pubitemid 32695384)
13. van der Velde N. M. et al. Time to stop ovarian cancer screening in BRCA1/2 mutation carriers? Int J Cancer: 2009; 124 919 923
14. Rustin G. J. et al. Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC55955): a randomised trial. Lancet: 2010; 376 1155 1163
15. Forstner R. et al. ESUR guidelines: ovarian cancer staging and follow-up. Eur Radiol: 2010; 20 2773 2780
16. Peng N. J. et al. Early detection of recurrent ovarian cancer in patients with low-level increases in serum CA-125 levels by 2-[F-18]fluoro-2-deoxy-D- glucose-positron emission tomography/computed tomography. Cancer Biother Radiopharm: 2011; 26 175 181
17. Gu P. et al. CA 125, PET alone, PET-CT, CT and MRI in diagnosing recurrent ovarian carcinoma: a systematic review and meta-analysis. Eur J Radiol: 2009; 71 164 174
18. Partridge E. E., Barnes M. N. Epithelial ovarian cancer: prevention, diagnosis, and treatment. CA Cancer J Clin: 1999; 49 297 320
19. ESMO ESMO minimum clinical recommendations for diagnosis, treatment and follow-up of ovarian cancer. Ann Oncol: 2001; 12 1205 1207
20. Jacobs I., Bast R. C. Jr. The CA 125 tumour-associated antigen: a review of the literature. Hum Reprod: 1989; 4 1 12 (Pubitemid 19069900)
21. IQWIG Positronenemissionstomographie (PET) und PET/CT bei Ovarialkarzinom. 2011. http://www.iqwiq.de
22. Torizuka T. et al. Ovarian cancer recurrence: role of whole-body positron emission tomography using 2-[fluorine-18]-fluoro-2-deoxy-D-glucose. Eur J Nucl Med Mol Imaging: 2002; 29 797 803
23. Takekuma M. et al. Positron emission tomography with 18F-fluoro-2- deoxyglucose for the detection of recurrent ovarian cancer. Int J Clin Oncol: 2005; 10 177 181 (Pubitemid 40933691)
24. Rebbeck T. R. et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med: 2002; 346 1616 1622 (Pubitemid 34755669)
25. Kauff N. D. et al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med: 2002; 346 1609 1615 (Pubitemid 34755668)
26. Haber D. Prophylactic oophorectomy to reduce the risk of ovarian and breast cancer in carriers of BRCA mutations. N Engl J Med: 2002; 346 1660 1662 (Pubitemid 34755676)
27. Finch A. et al. Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation. JAMA: 2006; 296 185 192
28. Rebbeck T. R. et al. PROSE Study Group Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol: 2005; 23 7804 7810 (Pubitemid 46657377)
29. Madalinska J. B. et al. The impact of hormone replacement therapy on menopausal symptoms in younger high-risk women after prophylactic salpingo-oophorectomy. J Clin Oncol: 2006; 24 3576 3582 (Pubitemid 46630529)
30. Parker W. H. et al. Ovarian conservation at the time of hysterectomy and long-term health outcomes in the nurses health study. Obstet Gynecol: 2009; 113 1027 1037
31. Madalinska J. B. et al. Quality-of-life effects of prophylactic salpingo-oophorectomy versus gynecologic screening among women at increased risk of hereditary ovarian cancer. J Clin Oncol: 2005; 23 6890 6898
32. Wagner T. M. et al. Attitude towards prophylactic surgery and effects of genetic counselling in families with BRCA mutations. Austrian Hereditary Breast and Ovarian Cancer Group. Br J Cancer: 2000; 82 1249 1253 (Pubitemid 30145340)
33. Hallowell N. A qualitative study of the information needs of high-risk women undergoing prophylactic oophorectomy. Psychooncology: 2000; 9 486 495 (Pubitemid 32010921)
34. Fry A. et al. Prophylactic oophorectomy versus screening: psychosocial outcomes in women at increased risk of ovarian cancer. Psychooncology: 2001; 10 231 241 (Pubitemid 32466048)
35. Antoniou A. et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet: 2003; 72 1117 1130 (Pubitemid 36530000)
36. Bonadona V. et al. Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome. JAMA: 2011; 305 2304 2310
37. Chen S. et al. Characterization of BRCA1 and BRCA2 mutations in a large United States sample. J Clin Oncol: 2006; 24 863 871 (Pubitemid 46638837)
38. Dreyer G. Screening for gynaecologic cancers in genetically predisposed women. Best Pract Res Clin Obstet Gynaecol: 2012; 26 267 282
39. Tinelli A. et al. Hereditary ovarian cancers: from BRCA mutations to clinical management. A modern appraisal. Cancer Metastasis Rev: 2010; 29 339 350
40. Malamou-Mitsi V. et al. Prognostic significance of HER-2, p 53 and Bcl-2 in patients with epithelial ovarian cancer. Anticancer Res: 2007; 27 1157 1165 (Pubitemid 46587035)
41. Kommoss S. et al. Independent prognostic significance of cell cycle regulator proteins p 16(INK4a) and pRb in advanced-stage ovarian carcinoma including optimally debulked patients: a translational research subprotocol of a randomised study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group. Br J Cancer: 2007; 96 306 313 (Pubitemid 46160636)
42. Secord A. A. et al. Co-expression of angiogenic markers and associations with prognosis in advanced epithelial ovarian cancer: a Gynecologic Oncology Group study. Gynecol Oncol: 2007; 106 221 232 (Pubitemid 46908745)
43. Bellati F. et al. Immunology of gynecologic neoplasms: analysis of the prognostic significance of the immune status. Curr Cancer Drug Targets: 2009; 9 541 565
44. Cree I. A. Chemosensitivity and chemoresistance testing in ovarian cancer. Curr Opin Obstet Gynecol: 2009; 21 39 43
45. Harry V. N., Gilbert F. J., Parkin D. E. Predicting the response of advanced cervical and ovarian tumors to therapy. Obstet Gynecol Surv: 2009; 64 548 560
46. Itamochi H., Kigawa J., Terakawa N. Mechanisms of chemoresistance and poor prognosis in ovarian clear cell carcinoma. Cancer Sci: 2008; 99 653 658 (Pubitemid 351448066)
47. Liu N., Wang X., Sheng X. 'Triple negative epithelial ovarian cancer and pathologic markers for prognosis. Curr Opin Obstet Gynecol: 2011; 23 19 23
48. Sabatier R. et al. Gene expression profiling and prediction of clinical outcome in ovarian cancer. Crit Rev Oncol Hematol: 2009; 72 98 109
49. Tian C. et al. CA-125 change after chemotherapy in prediction of treatment outcome among advanced mucinous and clear cell epithelial ovarian cancers: a Gynecologic Oncology Group study. Cancer: 2009; 115 1395 1403
50. Trainer A. H. et al. Moving toward personalized medicine: treatment-focused genetic testing of women newly diagnosed with ovarian cancer. Int J Gynecol Cancer: 2010; 20 704 716
51. Shaw M. C. et al. Development of an evidence-based algorithm for the management of ovarian cancer. Eur J Gynaecol Oncol: 2003; 24 117 125 (Pubitemid 36389351)
52. Ayhan A. et al. Oncologic and reproductive outcome after fertility-saving surgery in ovarian cancer. Eur J Gynaecol Oncol: 2003; 24 223 232 (Pubitemid 36644604)
53. Gershenson D. M. Fertility-sparing surgery for malignancies in women. J Natl Cancer Inst Monogr: 2005; 34 43 47
54. Morice P. et al. Conservative treatment in epithelial ovarian cancer: results of a multicentre study of the GCCLCC (Groupe des Chirurgiens de Centre de Lutte Contre le Cancer) and SFOG (Societe Francaise dOncologie Gynecologique). Hum Reprod: 2005; 20 1379 1385 (Pubitemid 40790267)
55. Leitao M. M. Jr., Chi D. S. Fertility-sparing options for patients with gynecologic malignancies. Oncologist: 2005; 10 613 622 (Pubitemid 41429124)
56. Dexeus S., Labastida R., Dexeus D. Conservative management of epithelial ovarian cancer. Eur J Gynaecol Oncol: 2005; 26 473 478 (Pubitemid 41585926)
57. Monk B. J., Disaia P. J. What is the role of conservative primary surgical management of epithelial ovarian cancer: the United States experience and debate. Int J Gynecol Cancer: 2005; 15 03 199 205 (Pubitemid 43096582)
58. Colombo N. et al. Role of conservative surgery in ovarian cancer: the European experience. Int J Gynecol Cancer: 2005; 15 03 206 211 (Pubitemid 43096583)
59. Marhhom E., Cohen I. Fertility preservation options for women with malignancies. Obstet Gynecol Surv: 2007; 62 58 72 (Pubitemid 46360535)
60. Denschlag D. et al. Clinical recommendation on fertility preservation in borderline ovarian neoplasm: ovarian stimulation and oocyte retrieval after conservative surgery. Gynecol Obstet Invest: 2010; 70 160 165
61. Sarnacki S., Brisse H. Surgery of ovarian tumors in children. Horm Res Paediatr: 2011; 75 220 224
62. Zanetta G. et al. Conservative surgery for stage I ovarian carcinoma in women of childbearing age. Br J Obstet Gynaecol: 1997; 104 1030 1035 (Pubitemid 27400184)
63. Schilder J. M. et al. Outcome of reproductive age women with stage IA or IC invasive epithelial ovarian cancer treated with fertility-sparing therapy. Gynecol Oncol: 2002; 87 1 7 (Pubitemid 36027095)
64. Morice P. et al. Results of conservative management of epithelial malignant and borderline ovarian tumours. Hum Reprod Update: 2003; 9 185 192 (Pubitemid 36582606)
65. Duska L. R. et al. Epithelial ovarian carcinoma in the reproductive age group. Cancer: 1999; 85 2623 2629 (Pubitemid 29272749)
66. Medeiros L. R. et al. Laparoscopy versus laparotomy for FIGO Stage I ovarian cancer. Cochrane Database Syst Rev: 2008; 4 CD005344
67. Trope C., Kaern J. Adjuvant chemotherapy for early-stage ovarian cancer: review of the literature. J Clin Oncol: 2007; 25 2909 2920 (Pubitemid 47123155)
68. Panici P. B. et al. Laparoscopy compared with laparoscopically guided minilaparotomy for large adnexal masses: a randomized controlled trial. Obstet Gynecol: 2007; 110 2 Pt 1 241 248 (Pubitemid 47356646)
69. Ghezzi F. et al. Should adnexal mass size influence surgical approach? A series of 186 laparoscopically managed large adnexal masses. BJOG: 2008; 115 1020 1027 (Pubitemid 351841784)
70. Fagotti A. et al. Should laparoscopy be included in the work-up of advanced ovarian cancer patients attempting interval debulking surgery? Gynecol Oncol: 2010; 116 72 77
71. Kindermann G., Maassen V., Kuhn W. Laparoscopic management of ovarian tumors subsequently diagnosed as malignant: a survey from 127 German departments of obstetrics and gynecology. J Pelvic Surgery: 1996; 2 245 251
72. Canis M. et al. Laparoscopic management of adnexal masses: a gold standard? Curr Opin Obstet Gynecol: 2002; 14 423 428 (Pubitemid 35001553)
73. Randall T. C., Rubin S. C. Surgical management of ovarian cancer. Semin Surg Oncol: 1999; 17 173 180 (Pubitemid 29477613)
74. Axtell A. E. et al. Multi-institutional reciprocal validation study of computed tomography predictors of suboptimal primary cytoreduction in patients with advanced ovarian cancer. J Clin Oncol: 2007; 25 384 389 (Pubitemid 350002986)
75. Wimberger P. et al. Influence of residual tumor on outcome in ovarian cancer patients with FIGO stage IV disease: an exploratory analysis of the AGO-OVAR (Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group). Ann Surg Oncol: 2010; 17 1642 1648
76. Gadducci A. et al. Relationship between time interval from primary surgery to the start of taxane- plus platinum-based chemotherapy and clinical outcome of patients with advanced epithelial ovarian cancer: results of a multicenter retrospective Italian study. J Clin Oncol: 2005; 23 751 758 (Pubitemid 46224174)
77. Trope C., Kaern J. Primary surgery for ovarian cancer. Eur J Surg Oncol: 2006; 32 844 852 (Pubitemid 44469295)
78. Bristow R. E. et al. Delaying the primary surgical effort for advanced ovarian cancer: a systematic review of neoadjuvant chemotherapy and interval cytoreduction. Gynecol Oncol: 2007; 104 480 490 (Pubitemid 46135675)
79. Wimberger P. et al. Prognostic factors for complete debulking in advanced ovarian cancer and its impact on survival. An exploratory analysis of a prospectively randomized phase III study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR). Gynecol Oncol: 2007; 106 69 74 (Pubitemid 46898573)
80. Vernooij F. et al. The outcomes of ovarian cancer treatment are better when provided by gynecologic oncologists and in specialized hospitals: a systematic review. Gynecol Oncol: 2007; 105 801 812 (Pubitemid 46734206)
81. Elit L. M. et al. Surgical outcomes in women with ovarian cancer. Can J Surg: 2008; 51 346 354
82. Gerestein C. G. et al. The prediction of progression-free and overall survival in women with an advanced stage of epithelial ovarian carcinoma. BJOG: 2009; 116 372 380
83. du Bois A. et al. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe dInvestigateurs Nationaux Pour les Etudes des Cancers de lOvaire (GINECO). Cancer: 2009; 115 1234 1244
84. Gerestein C. G. et al. Causes of postoperative mortality after surgery for ovarian cancer. Eur J Cancer: 2009; 45 2799 2803
85. Einenkel J. et al. Characteristics and management of diaphragm involvement in patients with primary advanced-stage ovarian, fallopian tube, or peritoneal cancer. Int J Gynecol Cancer: 2009; 19 1288 1297
86. Tixier H. et al. Evaluation of pelvic posterior exenteration in the management of advanced-stage ovarian cancer. Arch Gynecol Obstet: 2010; 281 505 510
87. Gerestein C. G. et al. Prediction of residual disease after primary cytoreductive surgery for advanced-stage ovarian cancer: accuracy of clinical judgment. Int J Gynecol Cancer: 2009; 19 1511 1515
88. Aletti G. D. et al. Identification of patient groups at highest risk from traditional approach to ovarian cancer treatment. Gynecol Oncol: 2011; 120 23 28
89. du Bois A. et al. Variations in institutional infrastructure, physician specialization and experience, and outcome in ovarian cancer: a systematic review. Gynecol Oncol: 2009; 112 422 436
90. Vergote I. et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med: 2010; 363 943 953
91. Schwartz P. E. et al. Neoadjuvant chemotherapy for advanced ovarian cancer: long-term survival. Gynecol Oncol: 1999; 72 93 99 (Pubitemid 29045454)
92. van der Burg M. E. et al. The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer. N Engl J Med: 1995; 332 629 634
93. Rose P. G. et al. Gynecologic Oncology Group Secondary surgical cytoreduction for advanced ovarian carcinoma. N Engl J Med: 2004; 351 2489 2497
94. Redman C. W. et al. Intervention debulking surgery in advanced epithelial ovarian cancer. Br J Obstet Gynaecol: 1994; 101 142 146 (Pubitemid 24195975)
95. Tangjitgamol S. et al. Interval debulking surgery for advanced epithelial ovarian cancer. Cochrane Database Syst Rev: 2010; 10 CD006014
96. Winter-Roach B. A., Kitchener H. C., Dickinson H. O. Adjuvant (post-surgery) chemotherapy for early stage epithelial ovarian cancer. Cochrane Database Syst Rev: 2009; 3 CD004706
97. Young R. C. et al. Adjuvant therapy in stage I and stage II epithelial ovarian cancer. Results of two prospective randomized trials. N Engl J Med: 1990; 322 1021 1027 (Pubitemid 20146659)
98. Trope C. et al. Are borderline tumors of the ovary overtreated both surgically and systemically? A review of four prospective randomized trials including 253 patients with borderline tumors. Gynecol Oncol: 1993; 51 236 243 (Pubitemid 24020371)
99. Trimbos J. B. et al. Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm trial. J Natl Cancer Inst: 2003; 95 113 125 (Pubitemid 36193260)
100. Timmers P. J. et al. Clear cell carcinoma compared to serous carcinoma in early ovarian cancer: same prognosis in a large randomized trial. Int J Gynecol Cancer: 2009; 19 88 93
101. Trimbos B. et al. Surgical staging and treatment of early ovarian cancer: long-term analysis from a randomized trial. J Natl Cancer Inst: 2010; 102 982 987
102. Adams G. et al. Platinum-based adjuvant chemotherapy for early-stage epithelial ovarian cancer: single or combination chemotherapy? BJOG: 2010; 117 1459 1467
103. Takano M. et al. Less impact of adjuvant chemotherapy for stage I clear cell carcinoma of the ovary: a retrospective Japan Clear Cell Carcinoma Study. Int J Gynecol Cancer: 2010; 20 1506 1510
104. Garcia-Saenz J. A. et al. Platinum-based adjuvant chemotherapy on moderate- and high-risk stage I and II epithelian ovarian cancer patients. Long-term single institution experience and literature review. Clin Transl Oncol: 2011; 13 121 132
105. Trimbos J. B. et al. International Collaborative Ovarian Neoplasm trial 1 and Adjuvant ChemoTherapy In Ovarian Neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma. J Natl Cancer Inst: 2003; 95 105 112 (Pubitemid 36196730)
106. Colombo N. et al. International Collaborative Ovarian Neoplasm trial 1: a randomized trial of adjuvant chemotherapy in women with early-stage ovarian cancer. J Natl Cancer Inst: 2003; 95 125 132 (Pubitemid 36193261)
107. Vergote I. et al. Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinoma. Lancet: 2001; 357 176 182 (Pubitemid 32108089)
108. Ho C. M. et al. Evaluation of complete surgical staging with pelvic and para-aortic lymphadenectomy and paclitaxel plus carboplatin chemotherapy for improvement of survival in stage I ovarian clear cell carcinoma. Gynecol Oncol: 2003; 88 394 399
109. Kitchener H. C. Adjuvant chemotherapy improves survival after resection of stage 1 ovarian cancer. Cancer Treat Rev: 2005; 31 323 327 (Pubitemid 41001680)
110. Shimada M. et al. Outcome of patients with early ovarian cancer undergoing three courses of adjuvant chemotherapy following complete surgical staging. Int J Gynecol Cancer: 2005; 15 601 605 (Pubitemid 41022896)
111. Bell J. et al. Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol: 2006; 102 432 439 (Pubitemid 44353663)
112. Obermair A. et al. A new prognostic model for FIGO stage 1 epithelial ovarian cancer. Gynecol Oncol: 2007; 104 607 611
113. Skirnisdottir I., Sorbe B. Survival and prognostic factors in early-stage epithelial ovarian carcinoma treated with taxane-based adjuvant chemotherapy. Int J Gynecol Cancer: 2007; 17 1231 1237 (Pubitemid 350077351)
114. Chan J. K. et al. Prognostic factors for high-risk early-stage epithelial ovarian cancer: a Gynecologic Oncology Group study. Cancer: 2008; 112 2202 2210 (Pubitemid 351628630)
115. Takano M. et al. Clear cell carcinoma of the ovary: a retrospective multicentre experience of 254 patients with complete surgical staging. Br J Cancer: 2006; 94 1369 1374 (Pubitemid 43772268)
116. Chan J. K. et al. The potential benefit of 6 vs. 3 cycles of chemotherapy in subsets of women with early-stage high-risk epithelial ovarian cancer: an exploratory analysis of a Gynecologic Oncology Group study. Gynecol Oncol: 2010; 116 301 306
117. Mannel R. S. et al. A randomized phase III trial of IV carboplatin and paclitaxel × 3 courses followed by observation versus weekly maintenance low-dose paclitaxel in patients with early-stage ovarian carcinoma: a Gynecologic Oncology Group Study. Gynecol Oncol: 2011; 122 89 94
118. NICE NICE clinical guideline 122. The recognition and initial management of ovarian cancer. 2011 [cited 2012 September 7]. http://guidance.nice.org.uk/ CG122 Stand: 07.09.2012
119. NHS National Institute for Health and Clinical Excellence Technology Appraisal Guidance 91 Paclitaxel, pegylated liposomal doxorubicin hydrochloride and topotecan for second-line or subsequent treatment of advanced ovarian cancer. 2005 [cited 2012 September 7]. http://www.nice.org.uk/TA091 Stand: 07.09.2012
120. ICON Collaborators ICON2: randomised trial of single-agent carboplatin against three-drug combination of CAP (cyclophosphamide, doxorubicin, and cisplatin) in women with ovarian cancer. ICON Collaborators. International Collaborative Ovarian Neoplasm Study. Lancet: 1998; 352 1571 1576
121. ICON Collaborators Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial. Lancet: 2002; 360 505 515
122. McGuire W. P. et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med: 1996; 334 1 6
123. Muggia F. M. et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study. J Clin Oncol: 2000; 18 106 115 (Pubitemid 30036343)
124. Neijt J. P. et al. Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer. J Clin Oncol: 2000; 18 3084 3092
125. Piccart M. J. et al. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst: 2000; 92 699 708 (Pubitemid 30365530)
126. West R. J., Zweig S. F. Meta-analysis of chemotherapy regimens for ovarian carcinoma: a reassessment of cisplatin, cyclophosphamide and doxorubicin versus cisplatin and cyclophosphamide. Eur J Gynaecol Oncol: 1997; 18 343 348 (Pubitemid 27437740)
127. Ozols R. F. Chemotherapy for ovarian cancer. Semin Oncol: 1999; 26 6 Suppl. 18 34 40 (Pubitemid 30013261)
128. du Bois A., Neijt J. P., Thigpen J. T. First line chemotherapy with carboplatin plus paclitaxel in advanced ovarian cancer - a new standard of care? Ann Oncol: 1999; 10 01 35 41
129. Aabo K. et al. Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patient data from 37 randomized trials. Advanced Ovarian Cancer Trialists Group. Br J Cancer: 1998; 78 1479 1487 (Pubitemid 28517545)
130. du Bois A. et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst: 2003; 95 1320 1329
131. Ozols R. F. et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol: 2003; 21 3194 3200 (Pubitemid 46606249)
132. Burger R. A. et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med: 2011; 365 2473 2483
133. Perren T. J. et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med: 2011; 365 2484 2496
134. McGuire W. P. 3rd. High-dose chemotherapeutic approaches to ovarian cancer management. Semin Oncol: 2000; 27(3 Suppl. 7) 41 46
135. Mobus V. et al. Phase III trial of high-dose sequential chemotherapy with peripheral blood stem cell support compared with standard dose chemotherapy for first-line treatment of advanced ovarian cancer: intergroup trial of the AGO-Ovar/AIO and EBMT. J Clin Oncol: 2007; 25 4187 4193 (Pubitemid 47548557)
136. Katsumata N. et al. Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet: 2009; 374 1331 1338
137. Hoskins P. et al. Advanced ovarian cancer: phase III randomized study of sequential cisplatin-topotecan and carboplatin-paclitaxel vs. carboplatin-paclitaxel. J Natl Cancer Inst: 2010; 102 1547 1556
138. Jaaback K., Johnson N. Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer. Cochrane Database Syst Rev: 2006; 1 CD005340
139. Buyse M. et al. Using the expected survival to explain differences between the results of randomized trials: a case in advanced ovarian cancer. J Clin Oncol: 2003; 21 1682 1687 (Pubitemid 46638578)
140. Aravantinos G. et al. Paclitaxel plus carboplatin versus paclitaxel plus alternating carboplatin and cisplatin for initial treatment of advanced ovarian cancer: long-term efficacy results: a Hellenic Cooperative Oncology Group (HeCOG) study. Ann Oncol: 2005; 16 1116 1122 (Pubitemid 41418314)
141. Dizon D. S. et al. Two for good measure: six versus eight cycles of carboplatin and paclitaxel as adjuvant treatment for epithelial ovarian cancer. Gynecol Oncol: 2006; 100 417 421 (Pubitemid 43075279)
142. Armstrong D. K. et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med: 2006; 354 34 43 (Pubitemid 43048949)
143. Grenman S. et al. A randomised phase III study comparing high-dose chemotherapy to conventionally dosed chemotherapy for stage III ovarian cancer: the Finnish Ovarian Cancer (FINOVA) study. Eur J Cancer: 2006; 42 2196 2199 (Pubitemid 44307617)
144. Spriggs D. R. et al. Phase III randomized trial of intravenous cisplatin plus a 24- or 96-hour infusion of paclitaxel in epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol: 2007; 25 4466 4471 (Pubitemid 350013853)
145. Lhomme C. et al. Phase III study of valspodar (PSC833) combined with paclitaxel and carboplatin compared with paclitaxel and carboplatin alone in patients with stage IV or suboptimally debulked stage III epithelial ovarian cancer or primary peritoneal cancer. J Clin Oncol: 2008; 26 2674 2682
146. Safra T. et al. Combined weekly carboplatin and paclitaxel as primary treatment of advanced epithelial ovarian carcinoma. Gynecol Oncol: 2009; 114 215 218
147. Lambert H. E. et al. A randomized trial of five versus eight courses of cisplatin or carboplatin in advanced epithelial ovarian carcinoma. A North Thames Ovary Group Study. Ann Oncol: 1997; 8 327 333 (Pubitemid 27230972)
148. Sorbe B. Swedish-Norgewian Ovarian Cancer Study Group Consolidation treatment of advanced (FIGO stage III) ovarian carcinoma in complete surgical remission after induction chemotherapy: a randomized, controlled, clinical trial comparing whole abdominal radiotherapy, chemotherapy, and no further treatment. Int J Gynecol Cancer: 2003; 13 278 286 (Pubitemid 38222574)
149. Mei L. et al. Maintenance chemotherapy for ovarian cancer. Cochrane Database Syst Rev: 2010; 9 CD007414
150. Berek J. et al. Oregovomab maintenance monoimmunotherapy does not improve outcomes in advanced ovarian cancer. J Clin Oncol: 2009; 27 418 425
151. Pecorelli S. et al. Phase III trial of observation versus six courses of paclitaxel in patients with advanced epithelial ovarian cancer in complete response after six courses of paclitaxel/platinum-based chemotherapy: final results of the After-6 protocol 1. J Clin Oncol: 2009; 27 4642 4648
152. Penson R. T. et al. Phase II study of carboplatin, paclitaxel, and bevacizumab with maintenance bevacizumab as first-line chemotherapy for advanced mullerian tumors. J Clin Oncol: 2010; 28 154 159
153. Pomel C. et al. Hyperthermic intra-peritoneal chemotherapy using oxaliplatin as consolidation therapy for advanced epithelial ovarian carcinoma. Results of a phase II prospective multicentre trial. CHIPOVAC study. Eur J Surg Oncol: 2010; 36 589 593
154. Hess L. M. et al. Continued chemotherapy after complete response to primary therapy among women with advanced ovarian cancer: a meta-analysis. Cancer: 2010; 116 5251 5260
155. Williams C., Simera I., Bryant A. Tamoxifen for relapse of ovarian cancer. Cochrane Database Syst Rev: 2010; 3 CD001034
156. ten Bokkel Huinink W. et al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol: 1997; 15 2183 2193
157. Parmar M. K. et al. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet: 2003; 361 2099 2106
158. Gordon A. N. et al. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol: 2001; 19 3312 3322 (Pubitemid 32642183)
159. Cantu M. G. et al. Randomized controlled trial of single-agent paclitaxel versus cyclophosphamide, doxorubicin, and cisplatin in patients with recurrent ovarian cancer who responded to first-line platinum-based regimens. J Clin Oncol: 2002; 20 1232 1237 (Pubitemid 34177429)
160. Blackledge G. et al. Response of patients in phase II studies of chemotherapy in ovarian cancer: implications for patient treatment and the design of phase II trials. Br J Cancer: 1989; 59 650 653 (Pubitemid 19111764)
161. Eisenhauer E. A. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer: 2009; 45 228 247
162. Rustin G. J. et al. Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG). Int J Gynecol Cancer: 2011; 21 419 423
163. Friedlander M. et al. Gynecologic Cancer InterGroup Clinical trials in recurrent ovarian cancer. Int J Gynecol Cancer: 2011; 21 771 775
164. Meier W. et al. Topotecan versus treosulfan, an alkylating agent, in patients with epithelial ovarian cancer and relapse within 12 months following 1st-line platinum/paclitaxel chemotherapy. A prospectively randomized phase III trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR). Gynecol Oncol: 2009; 114 199 205
165. ten Bokkel Huinink W., Lane S. R., Ross G. A. Long-term survival in a phase III, randomised study of topotecan versus paclitaxel in advanced epithelial ovarian carcinoma. Ann Oncol: 2004; 15 100 103 (Pubitemid 38139610)
166. Vergote I. et al. Phase 3 randomised study of canfosfamide (Telcyta, TLK286) versus pegylated liposomal doxorubicin or topotecan as third-line therapy in patients with platinum-refractory or -resistant ovarian cancer. 2009; (1879-0852 [Electronic])
167. Ferrandina G. et al. Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer. J Clin Oncol: 2008; 26 890 896 (Pubitemid 351398081)
168. Mutch D. G. et al. Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer. J Clin Oncol: 2007; 25 2811 2818 (Pubitemid 47123191)
169. du Bois A. et al. Chemotherapy versus hormonal treatment in platinum- and paclitaxel-refractory ovarian cancer: a randomised trial of the German Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) Study Group Ovarian Cancer. Ann Oncol: 2002; 13 251 257
170. Sehouli J. et al. Nonplatinum topotecan combinations versus topotecan alone for recurrent ovarian cancer: results of a phase III study of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group. J Clin Oncol: 2008; 26 3176 3182
171. Peng L. H., Chen X. Y., Wu T. X. Topotecan for ovarian cancer. Cochrane Database Syst Rev: 2008; 2 CD005589 10.1002/14651858.CD005589.pub2 (Pubitemid 351807464)
172. Eisenkop S. M., Friedman R. L., Spirtos N. M. The role of secondary cytoreductive surgery in the treatment of patients with recurrent epithelial ovarian carcinoma. Cancer: 2000; 88 144 153 (Pubitemid 30027690)
173. Harter P. et al. Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Committee; AGO Ovarian Cancer Study Group Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial. Ann Surg Oncol: 2006; 13 1702 1710 (Pubitemid 44951480)
174. Sehouli J. et al. Role of secondary cytoreductive surgery in ovarian cancer relapse: who will benefit? A systematic analysis of 240 consecutive patients. J Surg Oncol: 2010; 102 656 662
175. Galaal K. et al. Cytoreductive surgery plus chemotherapy versus chemotherapy alone for recurrent epithelial ovarian cancer. Cochrane Database Syst Rev: 2010; 6 CD007822
176. Bristow R. E., Puri I., Chi D. S. Cytoreductive surgery for recurrent ovarian cancer: a meta-analysis. Gynecol Oncol: 2009; 112 265 274
177. Harter P. et al. Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the Multicenter Intergroup Study DESKTOP II. A project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO. Int J Gynecol Cancer: 2011; 21 289 295
178. Kew F. et al. Evaluation of follow-up strategies for patients with epithelial ovarian cancer following completion of primary treatment. Cochrane Database Syst Rev: 2011; 6 CD006119
179. Gadducci A. et al. Surveillance procedures for patients treated for epithelial ovarian cancer: a review of the literature. Int J Gynecol Cancer: 2007; 17 21 31 (Pubitemid 46213965)
180. Guidozzi F., Daponte A. Estrogen replacement therapy for ovarian carcinoma survivors: A randomized controlled trial. Cancer: 1999; 86 1013 1018 (Pubitemid 29439856)
181. Eeles R. A. et al. Hormone replacement therapy and survival after surgery for ovarian cancer. BMJ: 1991; 302 259 262
182. Ursic-Vrscaj M., Bebar S., Zakelj M. P. Hormone replacement therapy after invasive ovarian serous cystadenocarcinoma treatment: the effect on survival. Menopause: 2001; 8 70 75 (Pubitemid 32066583)
183. Mascarenhas C. et al. Use of hormone replacement therapy before and after ovarian cancer diagnosis and ovarian cancer survival. Int J Cancer: 2006; 119 2907 2915 (Pubitemid 44846244)
184. WHO Classification of Tumours. Pathology and Genetics of Tumours of the Breast and female genital Organs. 3rd ed. Switzerland WHO-Press: 2003
185. Kaern J., Trope C. G., Abeler V. M. A retrospective study of 370 borderline tumors of the ovary treated at the Norwegian Radium Hospital from 1970 to 1982. A review of clinicopathologic features and treatment modalities. Cancer: 1993; 71 1810 1820 (Pubitemid 23067398)
186. Leake J. F. et al. Long-term follow-up of serous ovarian tumors of low malignant potential. Gynecol Oncol: 1992; 47 150 158 (Pubitemid 23001321)
187. Odegaard E. et al. Surgery of borderline tumors of the ovary: retrospective comparison of short-term outcome after laparoscopy or laparotomy. Acta Obstet Gynecol Scand: 2007; 86 620 626 (Pubitemid 46676326)
188. Camatte S. et al. Impact of surgical staging in patients with macroscopic "stage Io" ovarian borderline tumours: analysis of a continuous series of 101 cases. Eur J Cancer: 2004; 40 1842 1849 (Pubitemid 39036758)
189. Menczer J., Chetrit A., Sadetzki S. The effect of hysterectomy on survival of patients with borderline ovarian tumors. Gynecol Oncol: 2012; 125 372 375
190. du Bois A., Ewald-Riegler N. Borderline-Tumoren des Ovars - eine systematische Übersicht. Geburtsh Frauenheilk: 2009; 69 807 833
191. Morice P. et al. Recommendations of the Fertility Task Force of the European Society of Gynecologic Oncology about the conservative management of ovarian malignant tumors. Int J Gynecol Cancer: 2011; 21 951 963
192. Faluyi O. et al. Interventions for the treatment of borderline ovarian tumours. Cochrane Database Syst Rev: 2010; 9 CD007696
193. Miller B. E. et al. Prognostic factors in adult granulosa cell tumor of the ovary. Cancer: 1997; 79 1951 1955 (Pubitemid 27200379)
194. Nosov V. et al. Predictors of recurrence of ovarian granulosa cell tumors. Int J Gynecol Cancer: 2009; 19 628 633
195. Colombo N. et al. Management of ovarian stromal cell tumors. J Clin Oncol: 2007; 25 2944 2951 (Pubitemid 47123159)
196. Sehouli J. et al. Granulosa cell tumor of the ovary: 10 years follow-up data of 65 patients. Anticancer Res: 2004; 24 2C 1223 1229 (Pubitemid 38624966)
197. Zanagnolo V., Pasinetti B., Sartori E. Clinical review of 63 cases of sex cord stromal tumors. Eur J Gynaecol Oncol: 2004; 25 431 438 (Pubitemid 38954517)
198. Evans A. T. 3rd et al. Clinicopathologic review of 118 granulosa and 82 theca cell tumors. Obstet Gynecol: 1980; 55 231 238
199. Zhang M. et al. Prognostic factors responsible for survival in sex cord stromal tumors of the ovary - an analysis of 376 women. Gynecol Oncol: 2007; 104 396 400 (Pubitemid 46156957)
200. Fotopoulou C. et al. Adult granulosa cell tumors of the ovary: tumor dissemination pattern at primary and recurrent situation, surgical outcome. Gynecol Oncol: 2010; 119 285 290
201. Zambetti M. et al. cis-platinum/vinblastine/bleomycin combination chemotherapy in advanced or recurrent granulosa cell tumors of the ovary. Gynecol Oncol: 1990; 36 317 320 (Pubitemid 20116900)
202. Colombo N. et al. Cisplatin, vinblastine, and bleomycin combination chemotherapy in metastatic granulosa cell tumor of the ovary. Obstet Gynecol: 1986; 67 265 268 (Pubitemid 16135576)
203. Mahdi H. et al. Prognostic impact of lymphadenectomy in clinically early stage malignant germ cell tumour of the ovary. Br J Cancer: 2011; 105 493 497
204. Gershenson D. M. Management of ovarian germ cell tumors. J Clin Oncol: 2007; 25 2938 2943 (Pubitemid 47123158)
205. Pectasides D., Pectasides E., Kassanos D. Germ cell tumors of the ovary. Cancer Treat Rev: 2008; 34 427 441
206. Kumar S. et al. The prevalence and prognostic impact of lymph node metastasis in malignant germ cell tumors of the ovary. Gynecol Oncol: 2008; 110 125 132
207. Oltmann S. C. et al. Pediatric ovarian malignancies: how efficacious are current staging practices? J Pediatr Surg: 2010; 45 1096 1102
208. Gobel U. et al. Treatment of germ cell tumors in children: results of European trials for testicular and non-testicular primary sites. Crit Rev Oncol Hematol: 1990; 10 89 98 (Pubitemid 20233500)
209. Marina N. M. et al. Complete surgical excision is effective treatment for children with immature teratomas with or without malignant elements: a Pediatric Oncology Group/Childrens Cancer Group Intergroup Study. J Clin Oncol: 1999; 17 2137 2143 (Pubitemid 29318846)
210. Gershenson D. M. et al. Second-look laparotomy in the management of malignant germ cell tumors of the ovary. Obstet Gynecol: 1986; 67 789 793 (Pubitemid 16060039)
211. Billmire D. et al. Outcome and staging evaluation in malignant germ cell tumors of the ovary in children and adolescents: an intergroup study. J Pediatr Surg: 2004; 39 424 429 discussion 424-429 (Pubitemid 38338361)
212. Beiner M. E. et al. Cystectomy for immature teratoma of the ovary. Gynecol Oncol: 2004; 93 381 384 (Pubitemid 38507605)
213. Cushing B. et al. Surgical resection alone is effective treatment for ovarian immature teratoma in children and adolescents: a report of the Pediatric Oncology Group and the Childrens Cancer Group. Am J Obstet Gynecol: 1999; 181 353 358 (Pubitemid 29409913)
214. Kang H. et al. Outcome and reproductive function after cumulative high-dose combination chemotherapy with bleomycin, etoposide and cisplatin (BEP) for patients with ovarian endodermal sinus tumor. Gynecol Oncol: 2008; 111 106 110
215. Chan J. K. et al. Association of lymphadenectomy and survival in stage I ovarian cancer patients. Obstet Gynecol: 2007; 109 12 19 (Pubitemid 46043192)
216. Kim H. S. et al. Systematic lymphadenectomy for survival in epithelial ovarian cancer: a meta-analysis. Int J Gynecol Cancer: 2010; 20 520 528
217. Maggioni A. et al. Randomised study of systematic lymphadenectomy in patients with epithelial ovarian cancer macroscopically confined to the pelvis. Br J Cancer: 2006; 95 699 704 (Pubitemid 44373484)
218. Suzuki S. et al. Is there any association between retroperitoneal lymphadenectomy and survival benefit in ovarian clear cell carcinoma patients? Ann Oncol: 2008; 19 1284 1287 (Pubitemid 351911958)
219. Yang X. et al. Prognosis in epithelial ovarian cancer: clinical analysis of 287 pelvic and para-aortic lymphadenectomy. Chinese-German Journal of Clinical Oncology: 2007; 6 492 496
220. Yokoyama Y. et al. Evaluation of cytoreductive surgery with pelvic and paraaortic lymphadenectomy and intermittent cisplatin-based combination chemotherapy for improvement of long-term survival in ovarian cancer. Eur J Gynaecol Oncol: 1999; 20 361 366
221. Young R. C. et al. Staging laparotomy in early ovarian cancer. JAMA: 1983; 250 3072 3076 (Pubitemid 14201622)
222. Piver M. S., Barlow J. J., Lele S. B. Incidence of subclinical metastasis in stage I and II ovarian carcinoma. Obstet Gynecol: 1978; 52 100 104 (Pubitemid 8355351)
223. Buchsbaum H. J. et al. Surgical staging of carcinoma of the ovaries. Surg Gynecol Obstet: 1989; 169 226 232 (Pubitemid 19255049)
224. Griffiths C. T. Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. Natl Cancer Inst Monogr: 1975; 42 101 104
225. Hoskins W. J. et al. The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: a Gynecologic Oncology Group study. Gynecol Oncol: 1992; 47 159 166 (Pubitemid 23001322)
226. Hacker N. F. et al. Primary cytoreductive surgery for epithelial ovarian cancer. Obstet Gynecol: 1983; 61 413 420 (Pubitemid 13158699)
227. Hunter R. W., Alexander N. D., Soutter W. P. Meta-analysis of surgery in advanced ovarian carcinoma: is maximum cytoreductive surgery an independent determinant of prognosis? Am J Obstet Gynecol: 1992; 166 504 511
228. Allen D. G., Heintz A. P., Touw F. W. A meta-analysis of residual disease and survival in stage III and IV carcinoma of the ovary. Eur J Gynaecol Oncol: 1995; 16 349 356
229. Voest E. E., van Houwelingen J. C., Neijt J. P. A meta-analysis of prognostic factors in advanced ovarian cancer with median survival and overall survival (measured with the log (relative risk] as main objectives. Eur J Cancer Clin Oncol: 1989; 25 711 720 (Pubitemid 19096441)
230. Nguyen H. N. et al. National survey of ovarian carcinoma. Part V. The impact of physicians specialty on patients survival. Cancer: 1993; 72 3663 3670
231. Junor E. J. et al. Specialist gynaecologists and survival outcome in ovarian cancer: a Scottish national study of 1866 patients. Br J Obstet Gynaecol: 1999; 106 1130 1136 (Pubitemid 29495411)
232. Bristow R. E. et al. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol: 2002; 20 1248 1259 (Pubitemid 34177431)
233. Elattar A. et al. Optimal primary surgical treatment for advanced epithelial ovarian cancer. Cochrane Database Syst Rev: 2011; 8 CD007565
234. Ang C. et al. Ultra-radical (extensive) surgery versus standard surgery for the primary cytoreduction of advanced epithelial ovarian cancer. Cochrane Database Syst Rev: 2011; 4 CD007697
235. Bashir S. et al. Surgical technique of diaphragm full-thickness resection and trans-diaphragmatic decompression of pneumothorax during cytoreductive surgery for ovarian cancer. Gynecol Oncol: 2010; 119 255 258
236. Sehouli J. et al. Primary versus interval debulking surgery in advanced ovarian cancer: results from a systematic single-center analysis. Int J Gynecol Cancer: 2010; 20 1331 1340
237. Pfisterer J. et al. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol: 2006; 24 4699 4707 (Pubitemid 46630933)
238. Pujade-Lauraine E. et al. Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. J Clin Oncol: 2010; 28 3323 3329.